.png)
Klaus Vedfelt
4D Molecular Therapeutics (NASDAQ:FDMT) announced a significant workforce reduction of approximately 25% of its current and planned positions to streamline operations.
The company is also speeding up its 4D-150 4FRONT phase 3 program aimed at treating wet age-related macular degeneration.
English (US) ·